Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes by Machado-Neto, João Agostinho et al.
CLINICAL SCIENCE
Screening for hotspot mutations in PI3K, JAK2, FLT3
and NPM1 in patients with myelodysplastic
syndromes
Joa ˜o Agostinho Machado-Neto, Fabiola Traina, Mariana Lazarini, Paula de Melo Campos, Katia Borgia
Barbosa Pagnano, Irene Lorand-Metze, Fernando Ferreira Costa, Sara T Olalla Saad
Hematology and Hemotherapy Center, National Institute of Blood, University of Campinas, Sa ˜o Paulo, Brazil.
INTRODUCTION: Myelodysplastic syndromes encompass a heterogeneous group of clonal hematopoietic stem cell
disorders characterized by ineffective hematopoiesis, refractory cytopenia and a tendency to progress toward acute
myeloid leukemia. The accumulation of genetic alterations is closely associated with the progression of
myelodysplastic syndromes toward acute myeloid leukemia.
OBJECTIVE: To investigate the presence of mutations in the points most frequent for mutations (hotspot mutations)
in phosphatidylinositol-3-kinase (PI3K), Janus kinase 2 (JAK2), FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin
(NPM1), which are involved in leukemia and other cancers, in a population of Brazilian MDS patients.
METHODS: Fifty-one myelodysplastic syndromes patients were included in the study. According to French-American-
British classification, the patients were distributed as follows: 31 with refractory anemia, 8 with refractory anemia
with ringed sideroblasts, 7 with refractory anemia with excess blasts, 3 with refractory anemia with excess blasts in
transformation and 2 with chronic myelomonocytic leukemia. Bone marrow samples were obtained and screened
for the presence of hotspot mutations using analysis based on amplification with the polymerase chain reaction,
sequencing, fragment size polymorphisms or restriction enzyme digestion. All patients were screened for mutations
at the time of diagnosis, and 5 patients were also screened at the time of disease progression.
RESULTS: In the genes studied, no mutations were detected in the patients at the time of diagnosis. One patient
with chronic myelomonocytic leukemia was heterozygous for a Janus kinase 2 mutation after disease progression.
CONCLUSIONS: These results show that hotspot mutations in the PI3K, JAK2, FLT3 and NPM1 genes are not common
in MDS patients; nevertheless, JAK2 mutations may be present in myelodysplasia during disease progression.
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INTRODUCTION
Myelodysplastic syndromes (MDS) encompass a hetero-
geneous group of clonal hematopoietic stem cell disorders
characterized by ineffective hematopoiesis, refractory cytope-
nia and a tendency to progress to acute myeloid leukemia
(AML).
1 Low-risk MDS present high levels of intramedullar
apoptosis, whereas high-risk MDS show a decrease in apop-
tosis, an increase in cell proliferation and a high frequency of
evolution to AML.
2,3 The accumulation of genetic alterations is
closely associated with the progression of MDS toward AML,
and efforts are being made to determine the significance of
various genetic aberrations in patients with MDS.
4-6 The same
occurs for liver adenomatosis,
7 Rubinstein-taybi syndrome
8
and hemochromatosis.
9
The Phosphatidylinositol-3-kinase (PI3K) and Janus
kinase 2 (JAK2) signaling pathways are involved in
numerous cellular processes, such as proliferation, apopto-
sis and differentiation.
10-12 Mutations in the catalytic
subunit of PI3K are frequently observed in several cancers,
including AML.
4,5,13 Hotspot mutations occur in exon 9
(E542 and E545) and in exon 20 (H1047), resulting in
increased PI3K/Akt activity.
5,14-17 One somatic mutation in
the JAK2 gene (V617F) has been identified in myeloproli-
ferative disorders such as polycythemia vera (PV) and
myelofibrosis.
18
FMS-like tyrosine kinase 3 (FLT3) is a tyrosine kinase re-
ceptor that plays an important role in the proliferationand dif-
ferentiation of hematopoietic progenitors.
19 Nucleophosmin
(NPM1) is a key regulator of hematopoesis that shuttles
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793between the nucleus and cytoplasm. NPM1 mutations often
result in the predominant localization of the protein to the
cytoplasm, leading to destabilization of p14ARF and to the
inhibition of p53.
20 Internal tandem duplications (ITDs) in FLT3
and NPM1 mutations are frequent events in the development of
AML, and are associated with prognosis. According to Gale
et al,
21 it is possible to identify 3 prognostic groups based in the
presence or absence of FTL3 and NPM1 mutations: good (FLT3-
ITD
2NPM1
+), intermediate (FLT3-ITD
2NPM1
2 or FLT3-
ITD
+NPM1
+), and poor prognosis (FLT3-ITD
+NPM1
2).
Furthermore, a point mutation in exon 20 of the FLT3 gene
(FLT3-D835) has been described in a case of AML.
19
Mutations in PI3K, JAK2, FLT3 and NPM1 have been
described in cases of MDS; however, additional studies are
necessary to clarify their role in this disease. In this context,
the objective of this work was to investigate the occurrence of
the hotspot mutations E542, E545 and H1047 in PI3K, V617F
in JAK2, ITDs and D835 in FLT3 and exon 12 mutations in
NPM1 in MDS patients in a Brazilian population.
MATERIALS AND METHODS
Patients
DNA samples were obtained from bone marrow aspirates
of 51 patients diagnosed with de novo MDS. According to the
French-American-British (FAB) classification,
22 the patients
were classified as follows: 31 cases of refractory anemia (RA),
8 cases of refractory anemia with ringed sideroblasts (RARS),
7 cases of refractory anemia with excess blasts (RAEB), 3
cases of refractory anemia with excess blasts in transforma-
tion (RAEBt), and 2 cases of chronic myelomonocytic
leukemia (CMML). Using the World Health Organization
(WHO) 2008 classification guidelines,
23 there were 3 cases of
refractory cytopenia with unilineage dysplasia (RCUD), 23
cases of refractory cytopenia with multilineage dysplasia
(RCMD), 8 cases of refractory anemia with ring sideroblasts
(RARS), 3 cases of MDS associated with isolated del(5q)
(MDS-5q), 7 cases of refractory anemia with excess blast-1
(RAEB-1), 3 cases of refractory anemia with excess blast-2
(RAEB-2) and 4 cases of AML with multilineage dysplasia.
Samples were obtained at the time of diagnosis, and none of
the patients had received any cytotoxic drugs or growth
factors for MDS treatment. Patient characteristics are shown
in Table 1. Additionally, among the 51 patients evaluated at
the time of diagnosis, 5 patients presented disease progres-
sion and were screened for mutations after disease evolution.
Patient characteristics at diagnosis and after disease progres-
sion are shown in Table 2. Samples were collected at the
Hematology and Hemotherapy Center of the University of
Campinas, Brazil. All patients who contributed to this study
provided informed written consent, and the National Ethical
Committee Board approved the study.
Nucleic acid isolation
Genomic DNA was extracted from mononuclear bone
marrow cells with the GFX
TM Genomic Blood DNA
Purification Kit (Amersham Biosciences, Piscataway, USA),
according to the manufacturer’s instructions.
Detection of FLT3-ITD and NPM1 mutations
Identification of FLT3-ITD and NPM1 exon 12 mutations
was performed using polymerase chain reaction (PCR) and
analysis of fragment size. PCR was performed in a 50-mL
reaction volume consisting of 100 ng of genomic DNA, 5 mL
of 10X reaction buffer, 2 mL of 50 mM MgCl2, 2.5 units of Taq
Table 1 - Patient characteristics.
Number of individuals
MDS patients 51
Age in years: median (range): 63 (26-90)
Gender
30/21 M/F
FAB
RA/RARS 31/8
RAEB/RAEBt 7/3
CMML 2
WHO
RCUD/RCMD/RARS/SMD-5q 3/24/8/3
RAEB-1/RAEB-2 4/2
CMML1 2
AML with myelodysplasia-related changes 4
MDS Unclassified 1
Abbreviations- FAB: French-American-British; RA, refractory anemia;
RARS, refractory anemia with ringed sideroblasts; RAEB, refractory
anemia with excess blasts; RAEBt, refractory anemia with excess blasts in
transformation; CMML, chronic myelomonocytic leukemia; WHO, World
Health Organization; RCUD, refractory cytopenia with unilineage
dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; SMD-
5q, MDS associated with isolated del(5q); RAEB-1, refractory anemia with
excess blasts 1; RAEB-2, refractory anemia with excess blasts 2; CMML1,
chronic myelomonocytic leukemia 1; AML, acute myeloid leukemia.
Table 2 - Patient characteristics at diagnosis and after disease progression.
MDS
patient
Classification at
diagnosis (FAB/WHO)
Number of blasts
at diagnosis
Classification after disease
progression (FAB/WHO)
Number of blasts after
disease progression
Mutations after
disease
progression
Case 1 CMML/CMML1 3% CMML/CMML2 10% JAKV617F mutation
Case 2 RA/RCMD 0% RAEB/RAEB-1 12.5% None
Case 3 RA/RCMD 3% RAEBt/RAEB-2 10% None
Case 4 RARS/RARS
4% LMA/LMA with
myelodysplasia-related
changes
69% None
Case 5 RA/RCMD 1% RAEBt/RAEB-2 20% None
Abbreviations- MDS: myelodysplastic syndromes; FAB: French-American-British; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts;
RAEB, refractory anemia with excess blasts; RAEBt, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia;
WHO, World Health Organization; RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anemia with excess blasts 1; RAEB-2,
refractory anemia with excess blasts 2; CMML1, chronic myelomonocytic leukemia 1; CMML2, chronic myelomonocytic leukemia 2; AML, acute myeloid
leukemia.
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794polymerase and 200 nM each of the forward and reverse
primers(Table 3).Thereactionconditionswere set asfollows:
5 minutes of denaturing at 94˚C followed by 35 cycles of 20
seconds at 92˚C, 30 seconds at 57˚C and 45 seconds at 72˚C,
with a final step at 72˚C for 7 minutes. After dilution (1:20) in
water, 1 mL of each PCR product was mixed with 9 mL of Hi-
Di formamide (Applied Biosystems, Foster City, CA) and
0.5 mL of GeneScan 500-ROX size marker, and the mixture
was denatured for 5 minutes at 95˚C. Samples harboring the
mutation were identified based on the areas under the curves
representing the wild-type (FLT3:397 bp and NPM1:294 bp)
and mutated alleles (FLT3-ITD.397 bp and NPM1.294 bp).
AML patients with FLT3-ITD or NPM1 mutations were used
as positive controls.
Detection of the JAK2 V617F and FLT3-D835
mutations
Identification of JAK2 and FLT3 genotypes was performed
using PCR-restriction fragment length polymorphism (PCR-
RFLP) analysis. PCR was performed in a 50-mL reaction
volume consisting of 100 ng of genomic DNA, 5 mL of 10X
reaction buffer, 2 mL of 50 mM MgCl2, 2.5 units of Taq
polymerase and 200 nM each of the forward and reverse
primers(Table3).Thereactionconditionsweresetasfollows:
Table 3 - Primer sequences and restriction enzymes
Gene Mutation Primers sequences Restriction enzyme site
FLT3 ITD F: 59-GCAATTTAGGTATGAAAGCCAGC-39
R: 59-CTTTCAGCATTTTGACGGCAACC-39(HEX)
NPM1 exon 12 F: 59-GTGGTAGAATGAAAAATAGAT-39(FAM)
R: 59-CTTGGCAATAGAACCTGGAC-39
JAK2 V617F F: 59-GGGTTTCCTCAGAACGTTGA-39 BsaXI
R: 59-TCATTGCTTTCCTTTTTCACAA-39
FLT3 D835 F: 59-CCGCCAGGAACGTGCTTG-39 Eco321
R:59-GCAGCCTCACATTGCCCC-39
PI3K exon 9 F: 59-TTACAGAGTAACAGACTAGC-39
R: 59-TTTTAGCACTTACCT GTGAC-39
PI3K exon 20 F: 59-AGCTATTCGACAGCAGTGCC-39
R: 59-TTGTGTGGAAGATCCAATCC-39
Figure 1 - PCR and Sequencing of exons 9 and 20 of PI3K. The fragment size of the exon 9 (A) and exon 20 (B) of PI3K are indicated in
the figure. In both figures A and B, lane 1: Ladder 100bp fragments; lane 2: negative control; lanes 3 and 4: amplicons obtained from
genomic DNA of patient MDS patients (RA). Representative PI3K sequencing from MDS patients, determined by automated sequence
analysis of exon 9 (C) and 20 (D). The localization of the most frequent hotspot mutations are highlighted in the figure.
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7955 minutes of denaturing at 94˚C followed by 35 cycles of 30
seconds at 92˚C, 30 seconds at 57˚C and 50 seconds at 72˚C,
with a final step at 72˚C for 7 minutes. For RFLP analysis,
JAK2 and FLT3 PCR products were digested with BsaXI or
Eco321 (New England Biolabs, Hitchin, UK), respectively,
according to the manufacturer’s protocol, and visualized on a
2.5% agarose gel. The normal genotype for JAK2 was
represented by a 460-bp fragment, and the heterozygous
genotype was represented by 460-bp, 241-bp and 189-bp
fragments, whereas the homozygous mutant genotype
produced 241-bp and 189-bp fragments. For FLT3-D835, the
normal genotype was represented by 68-bp and 46-bp
fragments, and the heterozygous genotype was represented
by 114-bp, 68-bp and 46-bp fragments, whereas the homo-
zygous mutant genotype produced only a 114-bp fragment.
AML or PV patients with FLT3-D835 and JAK2 V617F
mutations, respectively, were used as positive controls.
Detection of the PI3K E542, E545 and H1047
mutations
Screening for PI3K mutations was performed by sequen-
cing PCR products. PCR was performed in a 50-mL reaction
volume consisting of 100 ng of genomic DNA, 5 mLo f1 0 X
reaction buffer, 2 mL of 50 mM MgCl2, 2.5 units of Taq
polymerase and 200 nM each of the forward and reverse
primers (Table3).Thereactionconditionswere set asfollows:
5 minutes of denaturing at 94˚C followed by 35 cycles of 30
seconds at 94˚C, 50 seconds at 63˚C and 55 seconds at 72˚C,
with a final step at 72˚C for 7 minutes. Sequencing reactions
were performed in both directions with the ABI PRISM
Figure 2 - Fragment analysis of FLT3-ITD and NPM1 mutations. Representative fragment size analysis of a MDS patient with wild-type
alleles for FLT3 (A), an AML patient with the FLT3-ITD mutation (B), an MDS patient with wild-type NPM1 (C) and an AML patient with a
mutation in exon 12 of NPM1 (D). The arrows indicate the presence of the mutant allele.
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796BigDyeterminatorversion3.0cyclesequencing kit,according
to the manufacturer’s instructions, using either one of the
primers used for amplification (Table 3). After ethanol-
sodium acetate precipitation, samples were analyzed on the
ABI PRISM 3100 Genetic Analyzer.
RESULTS
PI3K mutation analysis
Samples from 51 MDS patients were screened for PI3K
mutations; all 51 samples were screened at diagnosis, and 5
were screened again after disease progression. We exam-
ined exons 9 and 20, as a previous report has shown that
over 75% of the PI3K mutations found in a large number of
cancers are present in these exons.
19 The sequencing of PCR
products showed the absence of mutations in exons 9 and 20
of the PI3K gene in all MDS patients. PCR products and the
sequences of exons 9 and 20 are presented in figure 1.
FLT3-ITD and NPM1 mutation analysis
Forty-six MDS patients were screened for FLT3-ITD and
NPM1 exon 12 mutations at diagnosis, and 5 of these
patients were also screened at the time of disease progres-
sion. AML patients with the FLT3-ITD or NPM1 mutations
were used as positive controls. Analysis of DNA samples
from the MDS patients showed that all samples included
fragments of normal size, indicating the absence of muta-
tions (figure 2).
JAK2 V617F and FLT3-D835 mutation analysis
Fifty-one MDS patients were screened for JAK2 V617F, and
forty-seven were screened for FLT3-D835 at the time of
diagnosis. Five patients were screen after disease progression.
One PV patient with JAK2 V617F and one AML patient with
FLT3-D835 were used as positive controls. RFLP analysis
showed the absence of JAK2 and FLT3-D835 mutations in all
MDS patients at the time of diagnosis. Interestingly, we
Figure 3 - JAK2 V617F genotyping. (A) PCR amplification of JAK2: lane 1: 100 bp ladder; lane 2: negative control; lanes 3 to 6 – 460-bp
amplicons obtained from the genomic DNA of a patient with PV (3), a CMML patient after disease progression (4) and two MDS
patients (with RA) (5 and 6). (B) BsaXI digestion: lane 1: 100 bp ladder, lane 2: negative control; lanes 3 and 4: digestion pattern
observed in a PV patient (3) and in the CMML patient positive for the JAK2 V617F allele after disease progression (4); lanes 5 and 6:
digestion pattern observed in two MDS patients (with RA) with wild-type JAK2 alleles.
Figure 4 - FLT3-D835 genotyping. (A) PCR amplification of FLT3: lane 1: 100 bp ladder; lane 2: negative control; lanes 4 to 5: 114-bp
amplicons obtained from the genomic DNA of patients with MDS (3-4) and AML (5). (B) Eco321 digestion: lane 1: 100 bp ladder, lane 2:
negative control; lanes 3 and 4: digestion pattern observed in two MDS patients negative for the FLT3-D835 allele, lane 5: digestion
pattern observed in an AML patient with the FLT3-D835 mutation.
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797observed the presence of the JAK2 V617F mutation in one
patientwithCMMLafterdiseaseprogression(case1;Table 2).
Figures 3 and 4 represent the RFLP analysis of the JAK2 V617
and FLT3-D835 mutations, respectively.
DISCUSSION
Acute leukemia results from a combination of muta-
tions and changes in protein function that lead to an
increase in proliferation and defects in differentiation and
apoptosis.
24 Although FLT3 and NPM1 mutations have
been described with great frequency in cases of AML,
25,26
these mutations were not detected in the MDS patients
included in this study. As the presence of these mutations
was investigated at the time of diagnosis, screening during
disease progression could be interesting. Pinheiro and
colleagues
27 have reported the acquisition of the FLT3-
ITD mutation in 2 of 50 MDS patients included in
their study one year after diagnosis. These patients
later progressed toward AML, suggesting that the ac-
quisition of this mutation may be related to leukemic
transformation.
JAK2 mutations were not found in the MDS patients in this
study at diagnosis. Interestingly, the JAK2 V617F mutation
was identified in one CMML patient after disease progres-
sion. Initially, this patient presented with fewer than 5% bone
marrow blasts and lacked the JAK2 V617F mutation. We
observed the presence of the JAK2 V617F mutation during
disease progression, with increased white blood cell (WBC)
counts and bone marrow blasts (at diagnosis: 9000 WBC/L,
3% bone marrow blasts; at disease progression: 60000 WBC/
L, 10% bone marrow blasts). JAK2 mutations occur in 10% of
CMML cases and are associated with clinical and morpho-
logical features.
28 The JAK2 V617F mutation leads to
constitutive activation of the JAK2/STAT3 pathway and
aberrant signaling, resulting in growth factor independence,
increased proliferation and differentiation failure.
29 In light
of thefrequency of these eventsduringMDSprogression, our
results suggest that the acquisition of JAK2 mutations may be
involved in disease progression and should be investigated
in more cases of MDS evolution. This finding is in agreement
with other authors.
30,31 A recent publication by Malcovati et
al.
31reported3patientswhoevolvedfromRARSwithnormal
platelet counts and wild-type JAK2 to RARS-T with JAK2
mutation at the time of transformation.
Mutations in exons 9 and 20 of the PI3K gene are
frequently described in cancer.
4,5,13 However, we did not
observe the presence of these mutations in the MDS patients
included in this study. Constitutive activation of PI3K
occurs in AML and high-risk MDS patients at diagnosis
32-34,
and mutations in exons 9 and 20 result in constitutive
activation of this protein.
5,14-17 The presence of PI3K
mutations in AML
5 justifies the evaluation of these muta-
tions in a larger number of MDS patients, as they represent a
possible factor involved in disease progression.
The presence or absence of these mutations has prog-
nostic value in AML,
21 and therefore, the investigation of
similar mutations in other myeloid diseases such as MDS
could be interesting in the context of developing targeted
therapies. The PI3K/Akt pathway has already been targeted
in acute leukemia, and specific PI3K inhibitors, such as
LY294002, have been tested in vitro.
35 Other members of the
PI3K signaling pathway have also been investigated as
targets for leukemia treatment. Clinical studies with
rapamycin analogues, which inhibitor mTOR, are currently
in phase II AML trials, alone or in combination with other
chemotherapeutics.
36 Furthermore, FLT3 inhibitors have
shown therapeutic activity in AML patients with FLT3
mutations,
37 and selective JAK2 inhibitors have been tested
in patients with JAK2 mutations.
38
In summary, our study has shown that mutations in the
JAK2,FLT3,NPM1and PI3K genes are not common in patients
with MDS at diagnosis and that JAK2 mutations may occur in
MDS during disease progression. Further studies may be
helpful to understand the involvement of genetic changes and
the impact of these mutations in MDS progression and in
different subgroups of patients with the disease.
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